jak
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| jak [2026/05/10 21:00] – [Acquired JAK2 somatic mutations and risk of myeloproliferative neoplasms] wh | jak [2026/05/10 21:00] (current) – [Acquired JAK2 somatic mutations and risk of myeloproliferative neoplasms] wh | ||
|---|---|---|---|
| Line 76: | Line 76: | ||
| *these phenotypes include: | *these phenotypes include: | ||
| * pre-malignant state of [[CHIP]] | * pre-malignant state of [[CHIP]] | ||
| - | * [[prv]], [[essential_thrombocytosis]] | + | * [[prv]] |
| + | * [[essential_thrombocytosis]] | ||
| * primary [[myelofibrosis]] | * primary [[myelofibrosis]] | ||
| *one third of JAK2 V617F positive PRV and PMF cases are homozygous with mutation burdens greater than 50% - this generally occurs as a consequence of mitotic recombination of chromosome 9p, and is referred to as acquired uniparental disomy (UPD) or copy number neutral loss of heterozygosity (CNN-LOH) | *one third of JAK2 V617F positive PRV and PMF cases are homozygous with mutation burdens greater than 50% - this generally occurs as a consequence of mitotic recombination of chromosome 9p, and is referred to as acquired uniparental disomy (UPD) or copy number neutral loss of heterozygosity (CNN-LOH) | ||
jak.txt · Last modified: 2026/05/10 21:00 by wh